Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Interactive:
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Quiz
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Exams
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions

Oncology


Answer 3
  1. Deep venous thrombosis. Treatment with tamoxifen leads to an increased risk for thromboembolic events, including stroke, pulmonary embolism, and deep venous thrombosis, as well as endometrial cancer because of its partial estrogenic activity.3 Heart failure is associated with trastuzumab and anthracycline (eg, doxorubicin) treatment. Acute leukemia and myelodysplastic syndrome is associated with alkylating agents (cyclophosphamide) and type II topoisomerase inhibitors (including anthracyclines). Radiation of the left chest wall also increases the risk of coronary artery disease. Hand and foot erythema with or without pain is a frequent acute adverse effect of capecitabine (5-fluorouracil) therapy.

    REFERENCE
    3. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351:1451–67.

Click here to return to the questions

 

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 1/04/08 • kkj